Cargando…

Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion

AIM: Fabry disease is caused by α-galactosidase A deficiency leading to accumulation of globotriaosylceramide (Gb(3)) in tissues. Clinical manifestations do not appear to correlate with total Gb(3) levels. Studies examining tissue distribution of specific acyl chain species of Gb(3) and upstream gly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamani, Mustafa A, Provençal, Philippe, Boutin, Michel, Pacienza, Natalia, Fan, Xin, Novak, Anton, Huang, Tonny C, Binnington, Beth, Au, Bryan C, Auray-Blais, Christiane, Lingwood, Clifford A, Medin, Jeffrey A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242178/ https://www.ncbi.nlm.nih.gov/pubmed/28116130 http://dx.doi.org/10.4155/fsoa-2016-0027

Ejemplares similares

ATP-binding cassette transporters mediate differential biosynthesis of glycosphingolipid species
por: Budani, Monique, et al.
Publicado: (2021)

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease
por: Üçeyler, Nurcan, et al.
Publicado: (2016)

Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease
por: Ishii, Satoshi, et al.
Publicado: (2020)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
por: Taguchi, Atsumi, et al.
Publicado: (2023)

Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy
por: Gaggl, Martina, et al.
Publicado: (2016)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
por: Namdar, Mehdi, et al.
Publicado: (2012)

Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres
por: Mhanni, Aizeddin A., et al.
Publicado: (2020)

Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
por: Kim, Jeong-Yup, et al.
Publicado: (2010)

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy
por: Liguori, Rocco, et al.
Publicado: (2017)

Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction
por: Yogasundaram, Haran, et al.
Publicado: (2018)

Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
por: Boutin, Michel, et al.
Publicado: (2020)

One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
por: Najafian, Behzad, et al.
Publicado: (2016)

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
por: Shin, Seok-Ho, et al.
Publicado: (2018)

Lentivirus-mediated gene therapy for Fabry disease
por: Khan, Aneal, et al.
Publicado: (2021)

Role of Globotriaosylceramide in Physiology and Pathology
por: Celi, Ana Beatriz, et al.
Publicado: (2022)

Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types
por: Welford, R W D, et al.
Publicado: (2018)

Neonatal Urine Screening Program in the Province of Quebec: Technological Upgrade from Thin Layer Chromatography to Tandem Mass Spectrometry
por: Auray-Blais, Christiane, et al.
Publicado: (2021)

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34(+) Cells for Correction of Fabry Disease
por: Huang, Ju, et al.
Publicado: (2017)

Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
por: Saleh, Amr H., et al.
Publicado: (2023)

Neonatal Mass Urine Screening Approach for Early Detection of Mucopolysaccharidoses by UPLC-MS/MS
por: Menkovic, Iskren, et al.
Publicado: (2019)

Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment
por: Mauer, Michael, et al.
Publicado: (2017)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
por: Birklé, Stéphane, et al.
Publicado: (2013)

Late-onset and classic phenotypes of Fabry disease in males with the GLA-Thr410Ala mutation
por: Valtola, Kati, et al.
Publicado: (2023)

Endoplasmic Reticulum-Targeted Subunit Toxins Provide a New Approach to Rescue Misfolded Mutant Proteins and Revert Cell Models of Genetic Diseases
por: Adnan, Humaira, et al.
Publicado: (2016)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
por: Bertoldi, Giovanni, et al.
Publicado: (2023)

MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease
por: Maier, Nadine, et al.
Publicado: (2021)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease
por: An, Jong Hun, et al.
Publicado: (2022)

Risk of Death in Heart Disease is Associated With Elevated Urinary Globotriaosylceramide
por: Schiffmann, Raphael, et al.
Publicado: (2014)

A biobank management model applicable to biomedical research
por: Auray-Blais, Christiane, et al.
Publicado: (2006)

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
por: Germain, Dominique P, et al.
Publicado: (2012)

Renal globotriaosylceramide deposits for Fabry disease linked to uncertain pathogenicity gene variant c.352C>T/p.Arg118Cys: A family study
por: Cerón‐Rodríguez, Magdalena, et al.
Publicado: (2019)

Identification of a Reliable Biomarker Profile for the Diagnosis of Gaucher Disease Type 1 Patients Using a Mass Spectrometry-Based Metabolomic Approach
por: Menkovic, Iskren, et al.
Publicado: (2020)

Glycosphingolipids as Receptors for Non-Enveloped Viruses
por: Taube, Stefan, et al.
Publicado: (2010)

Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry
por: Menkovic, Iskren, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5m6klaqbosmt6r3cbqmtthssoj